trial
as of 2026-07-01Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)
NCTId NCT00702793
at a glance
Phase 4 · Withdrawn
Enrollment 0 (actual)
Sponsored by University of British Columbia
Primary completion 2012-05
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2008-04
Primary completion
2012-05
Eligibility
ALL · 19 Years · 65 Years
Interventions & indications
Sponsors
University of British ColumbiaLead Sponsor
Investigators
6
Ric M. Procyshyn, Ph.DPrincipal Investigator
Alasdair M Barr, Ph.D.Study Director
Joyce Coutts, MDStudy Director
Sean Flynn, MDStudy Director
Chris Schenk, MDStudy Director
William G Honer, ProfessorStudy Director
Sites
0 total
Facts & assertions
4 sourced
Enrollment
0
Phase
PHASE4
Primary Completion Date
2012-05
Status
WITHDRAWN
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
investigator